ClouDr Group (FRA:H3L) Other Stockholders Equity: €1,443.3 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H3L ClouDr Group Ltd FRA:H3L
48 GF Score
Price €0.05
GF Value €0.08
! 9 Warning Signs
View Full Analysis

What is ClouDr Group Other Stockholders Equity?

ClouDr Group FRA:H3L 48 Other Stockholders Equity is €1,443.3 Mil as of Dec. 2025. GuruFocus rates FRA:H3L with a GF Score™ of 48/100 and a GF Value™ of €0.08. The stock has 9 warning signs investors should review.

ClouDr Group's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €1,443.3 Mil.

ClouDr Group's quarterly Other Stockholders Equity declined from Dec. 2024 (€1,559.2 Mil) to Jun. 2025 (€1,442.0 Mil) but then increased from Jun. 2025 (€1,442.0 Mil) to Dec. 2025 (€1,443.3 Mil).

ClouDr Group's annual Other Stockholders Equity increased from Dec. 2023 (€1,509.6 Mil) to Dec. 2024 (€1,559.2 Mil) but then declined from Dec. 2024 (€1,559.2 Mil) to Dec. 2025 (€1,443.3 Mil).

ClouDr Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ClouDr Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClouDr Group Other Stockholders Equity Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 106.29 1,554.61 1,509.55 1,559.15 1,443.34

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,509.55 1,514.89 1,559.15 1,442.04 1,443.34
FRA:H3L
48GF Score
ClouDr Group Ltd FRA:H3L
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClouDr Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €1,443.3 Mil mean?
ClouDr Group (FRA:H3L) has a Other Stockholders Equity of €1,443.3 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ClouDr Group and its competitors.
Is ClouDr Group's Other Stockholders Equity too high?
ClouDr Group's current Other Stockholders Equity is €1,443.3 Mil. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's Other Stockholders Equity compare to MCK and COR?
ClouDr Group's Other Stockholders Equity of €1,443.3 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Distribution company?
A good Other Stockholders Equity depends on the Medical Distribution industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ClouDr Group and its competitors. ClouDr Group's current Other Stockholders Equity is €1,443.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current Other Stockholders Equity of €1,443.3 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current Other Stockholders Equity is €1,443.3 Mil. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current Other Stockholders Equity is €1,443.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClouDr Group (FRA:H3L) Overvalued in 2026?

Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued. The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:H3L:

  • Other Stockholders Equity: €1,443.3 Mil
  • GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
  • GF Score™: 48/100 with 9 warning signs

No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClouDr Group Business Description

Other Exchanges 09955:Hong Kong
Address No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score

Get the complete analysis for FRA:H3L

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price
€0.08
GF Value